JPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont launch being off to a solid start and continued momentum elsewhere across the company’s portfolio for the upgrade. JPMorgan sees Amneal’s generics business as increasingly well positioned, with a portfolio more levered towards complex products and biosimilars. It sees these supporting sustainable high-single-digit growth over the next several years. The Crexont launch is trending ahead of expectations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Robust Growth and Strategic Positioning Drive Buy Rating for Amneal Pharmaceuticals
- Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
- Amneal gets FDA approval for memantine/donepezil extended-release capsules
- Amneal receives FDA tentative approval for ANDA for rifaximin
- Amneal Pharmaceuticals backs prior FY24 EPS view 57c-63c, consensus 61c